Table 2.
Clinicopathological features of EGFR-high, weak, and negative cases in HPV-related oropharyngeal carcinoma
| HPV-related oropharyngeal carcinoma (n = 52) | P value§ | P value | |||
|---|---|---|---|---|---|
| EGFR-high (n = 11) | EGFR-weak (n = 34) | EGFR-negative (n = 7) | |||
| Age | 0.04† | ||||
| Mean | 71.8 | 67.6 | 60.86 | ||
| Range | (62–86) | (44–62) | (50–79) | ||
| Sex—no. (%) | NS‡ | ||||
| Male | 10 (90.9) | 28 (82.4) | 5 (71.4) | ||
| Female | 1 (9.1) | 6 (17.6) | 2 (28.6) | ||
| Smoking history—no. (%) | NS‡ | ||||
| Never or former smoker | 10 (90.9) | 23 (67.6) | 5 (71.4) | ||
| Current smoker | 1 (9.1) | 6 (17.6) | 0 | ||
| Uncertain | 0 | 5 (14.7)) | 2 (28.6) | ||
| Drinking history—no. (%) | NS‡ | ||||
| Positive | 7 (63.6) | 23 (67.6) | 3 (42.9) | ||
| Negative | 2 (18.2) | 6 (17.6) | 3 (42.9) | ||
| Uncertain | 2 (18.2) | 5 (14.7) | 1 (14.3) | ||
| Tumor size | – | NS† | |||
| Mean (mm) | 28.6 | 28.0 | 24.0 | ||
| Range | (22–45) | (6–50) | (10–40) | ||
| Tumor site—no. (%) | NS‡ | ||||
| Lateral wall | 7 (63.6) | 27 (79.4) | 5 (71.4) | ||
| Upper wall | 0 | 0 | 1 (14.3) | ||
| Anterior wall | 3 (27.3) | 3 (8.8)) | 0 | ||
| Posterior wall | 0 | 0 | 0 | ||
| Uncertain | 1 (9.1) | 5 (14.7) | 1 (14.3) | ||
| T factor—no. (%) | NS‡ | ||||
| T1-2 | 8 (72.7) | 26 (76.5) | 6 (85.7) | ||
| T3-4 | 3 (27.3) | 8 (23.5) | 1 (14.3) | ||
| N factor—no. (%) | NS‡ | ||||
| N0 | 6 (54.5) | 7 (20.6) | 2 (28.6) | ||
| N1-3 | 5 (45.5) | 27 (79.4)) | 5 (71.4) | ||
| M factor—no. (%) | NS‡ | ||||
| M0 | 11 (100.0) | 34 (100.0) | 7 (100) | ||
| M1 | 0 | 0 | 0 | ||
| Stage—no. (%) | NS‡ | ||||
| I–II | 10 (90.9) | 32 (94.1) | 6 (85.7) | ||
| III–IV | 1 (9.1) | 2 (5.9) | 1 (14.3) | ||
| Prognosis | |||||
| Overall survival (%) | 100 | 94.1 | 100 | NS|| | |
| Progression free survival (%) | 72.7 | 73.5 | 71.4 | NS|| | |
| Histology | NS‡ | 0.035a | |||
| Keratinizing SCC | 6 (54.5) | 18 (52.9) | 0 |
|
|
| Hybrid SCC | 1 (9.1) | 9 (26.5) | 1 (14.3) | ||
| Non-keratinizing SCC | 4 (36.4) | 5 (14.7) | 5 (71.4) | ||
| Basaloid SCC | 0 | 1 (2.9) | 1 (14.3) | ||
| Lymphoepithelial carcinoma | 0 | 1 (2.9) | 0 | ||
| CK14 protein expression | 0.037‡ | ||||
| Positive | 6 (54.5) | 23 (67.6) | 1 (14.3) | ||
| Negative | 5 (45.5) | 11 (32.4) | 6 (85.7) | ||
| EGFR missense mutation—no. (%) | NS‡ | ||||
| Present | 1 (9.1) | 1 (2.9) | 1 (14.3) | ||
| Absent | 10 (90.9) | 33 (97.1) | 6 (85.7) | ||
| Q787Q synonymous mutation—no.(%) | NS‡ | ||||
| Present | 0 | 7 (20.6) | 2 (28.6) | ||
| Absent | 11 (100.0) | 27 (79.4) | 5 (71.4) | ||
| EGFR amplification—no.(%)¶ | NS‡ | ||||
| Present | 0 | 0 | 0 | ||
| Absent | 2 (100.0) | 5 (100.0) | 4 (100) | ||
| EGFR promoter methylation—no.(%)¶ | 0.009‡ | ||||
| Present | 2 (18.2) | 6 (17.6) | 5 (83.3) | ||
| Absent | 9 (81.8) | 28 (82.4) | 1 (14.3) | ||
| Associated HPV type—no.(%)¶ | NS‡ | 0.049b | |||
| Type16 | 4 (40.0) | 27 (79.4) | 3 (60.0) | ||
| Other types | 6 (60.0) | 7 (20.6) | 2 (40.0) | ||
¶Data of EGFR amplification are of 2 EGFR-high, 5 EGFR-weak, and 4 EGFR-negative cases. Data of EGFR promoter methylation are of 11 EGFR-high, 34 EGFR-weak, and 6 EGFR-negative cases. Data of HPV type are of 10 EGFR-high, 34 EGFR-weak, and 5 EGFR-negative cases
§NS not significant and the superscript letter
†Kruskal–Wallis test
‡Chi-square test
||Log-rank test, respectively
aP value between EGFR expression and histology by dividing histology into keratinizing SCC and other SCCs
bP value between EGFR expression and associated HPV types by dividing EGFR expression into -high/weak and -negative